Skip to main content

John T. Rudy

Member / Co-chair, Securities & Capital Markets Practice

[email protected]

+1.617.348.3050

Share:

John’s practice focuses on the representation of public and private companies and investment banks in capital markets transactions. He also advises public and private companies and investors in connection with mergers and acquisitions, equity and debt financings, and securities and general corporate matters.

Prior to joining Mintz, John was an associate at Davis Polk & Wardwell, LLP in New York, and at Willkie Farr & Gallagher, LLP in New York and London.

John received his J.D. from University of Pennsylvania Law School. He received a B.S.F.S. from Georgetown University School of Foreign Service. During law school, he was an associate editor of the Journal of International Economic Law.

John is admitted to practice in Massachusetts and New York.

viewpoints

Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.

Read more
Read less

News & Press

Press Release Thumbnail

Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.

News Thumbnail
Mintz Member John T. Rudy was quoted in an article published by Law360 on companies in the health care and energy industries updating their risk disclosures to warn investors of potential policy changes that could harm their businesses under a Biden administration. Mr. Rudy said that he expects companies will review disclosures from past years and update accordingly.
Mintz attorney John Rudy is quoted in this article on how U.S. companies eyeing billions of dollars in initial public offerings to kick off the new year are fast running out of time, as the U.S. government shutdown enters its 35th day.

Mintz Member John Rudy is quoted in this Bloomberg News story discussing how the ongoing government shutdown is impacting the initial public offerings (IPO) market.
Mintz represents NuCana, which completed its approximately $114 million initial public offering. The United Kingdom-based clinical-stage company focuses on improving treatment outcomes for patients with cancer.
Read less

Events & Speaking

Moderator
May
3
2023

Biotech Public CEO Forum

LSX World Congress

London, UK

Conference Reference Image
Panelist
Moderator
Speaker
Aug
28
2019
Moderator
Jun
19
2019

The Board Meeting

Belmont Country Club

Read less

Recognition & Awards

  • Included on the Massachusetts Super Lawyers list: Rising Star – Securities & Corporate Finance (2013 – 2014, 2017 – 2019)

  • Greater Boston Chamber of Commerce: Boston’s Future Leaders (2014)

Read less

John T. Rudy

Member / Co-chair, Securities & Capital Markets Practice

Boston